Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Res. 2011 Aug 5;9(10):1406–1417. doi: 10.1158/1541-7786.MCR-11-0227

Figure 2.

Figure 2

Lrig1 is elevated in ER-positive tumors. (A) Western blot analysis of lysates from ER-negative and ER-positive tumors. Tissue lysates were blotted for Lrig1 and actin (loading control). Representative samples shown. (B) Densitometric analysis of ER-negative (n = 14) and ER-positive (n = 27) tumors. (C) qPCR analysis of Lrig1 transcript in ZR75-1 breast cancer cells. Hormone starved cells were treated with either vehicle control (VC) or E2 for 4 or 8 hours. (D) qPCR analysis of Lrig1 transcript in ZR75-1 breast cancer cells. Hormone starved cells were treated for 72 hours with either vehicle control (VC), 10 nM E2, 10 nM E2 plus 1 μM tamoxifen or 10 nM E2 plus 100 nM Fulvestrant. Columns, representative experiment performed in triplicate from at least three independent experiments bars, standard deviation.

HHS Vulnerability Disclosure